Skip to main content

Table 2 Capmatinib safety overview NSCLC with METex14 skipping mutation (GEOMETRY mono-1)

From: Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer

Adverse events

Cohort 4 (N = 69)

Cohort 5b (N = 28)

Total

Grade 3 or 4

Total

Grade 3 or 4

Any event-no (%)

68 (99)

52 (75)

28 (100)

21 (75)

Peripheral edema

37 (54)

10 (14)

21 (75)

3 (11)

Nausea

31 (46)

0

13 (46)

0

Vomiting

18 (26)

0

7 (25)

0

Creatinine increased

23 (33)

0

10 (36)

0

Dyspnea

19 (28)

7 (10)

6 (21)

2 (7)

fatigue

18 (26)

6 (9)

4 (14)

1 (4)

Decreased appetite

15 (22)

1 (1)

8 (29)

0

Constipation

10 (14)

2 (3)

4 (14)

0

Diarrhea

12 (17)

0

5 (18)

0

Cough

10 (14)

1 (1)

7 (25)

0

Back pain

11 (16)

2 (3)

4 (14)

0

Pyrexia

9 (13)

1 (1)

2 (7)

0

ALT increased

8 (12)

6 (9)

4 (14)

2 (7)

Asthenia

6 (9)

3 (4)

4 (14)

2 (7)

Pneumonia

7 (10)

4 (6)

2 (7)

0

Weight loss

9 (13)

0

3 (11)

0

Non-cardiac chest pain

5 (7)

1 (1)

1 (4)

0

Serious AE

36 (52)

30 (43)

14 (50)

12 (43)

Event leading to discontinuation

14 (20)

8 (12)

6 (21)

5 (18)

  1. Cohort 4 are patients who had received one or two lines of therapy previously and cohort 5b are patients who had not received treatment previously. ALT denotes alanine aminotransferase (30)